Author: claimsbot

1. A centrifugal compressor comprising a rotary shaft, a circular plate supported by the rotary shaft, and a plurality of blades substantially radially disposed and protruding from the circular plate, and having flow channels formed between the blades, in order to suck fluid from a front area in a shaft direction by rotating the circular plate with the rotary shaft and then discharge the fluid, which increases in pressure while passing through the flow channels, in a centrifugal direction,
wherein, assuming that a blade angle of a shroud side facing the circular plate of the blade is a first angle and a blade angle of a hub side disposed at the circular plate is a second angle,
the shroud side is formed in a curved shape having an angle distribution from the front area in the shaft direction toward the centrifugal direction in which the first angle is the local maximum point before a substantially middle portion and the local minimum point after the substantially middle point, and
the hub side is formed in a curved shape having an angle distribution from the front area in the shaft direction toward the centrifugal direction in which the second angle is the maximum local point before the substantially middle portion.
2. A centrifugal compressor comprising a rotary shaft, a circular plate supported by the rotary shaft, and a plurality of blades substantially radially disposed and protruding from the circular plate, and having flow channels formed between the blades, in order to suck fluid from a front area in a shaft direction by rotating the circular plate with the rotary shaft and then discharge the fluid, which increases in pressure while passing through the flow channels, in a centrifugal direction,
wherein, assuming that a blade angle of a shroud side facing the circular plate of the blade is a first angle and a blade angle of a hub side disposed at the circular plate is a second angle,
the shroud side is formed in a curved shape having a plurality of angle distributions from the front area in the shaft direction toward the centrifugal direction in which the first angle is alternately the local maximum point and the local minimum point, and
the hub side is formed in a curved shape having an angle distribution from the front area in the shaft direction toward the centrifugal direction in which the second angle is the local maximum point before a substantially middle portion.
3. A centrifugal compressor comprising a rotary shaft, a circular plate supported by the rotary shaft, and a plurality of blades substantially radially disposed and protruding from the circular plate, and having flow channels formed between the blades, in order to suck fluid from a front area in a shaft direction by rotating the circular plate with the rotary shaft and then discharge the fluid, which increases in pressure while passing through the flow channels, in a centrifugal direction,
a flow channel adjacent to a fluid intake of the shroud side of the blade facing the circular plate of the blade is enlarged and at least one of a flow channel adjacent to a fluid outlet of the shroud side and a fluid outlet of the hub side at the circular plate is reduced.
4. The centrifugal compressor according to claim 3, wherein the flow channel adjacent to the fluid intake is enlarged by tapering the shroud side at a predetermined angle in the shaft direction, and
the flow channel adjacent to the fluid outlet of the shroud side or the fluid outlet of the hub side at the circular plate is reduced by tapering the shroud side toward the centrifugal direction at a predetermined angle.
5. The centrifugal compressor according to claims 1, wherein an angle made by a straight line connecting the shroud side of the fluid outlet with the hub side and an edge of the circular plate that is perpendicular to the rotary shaft is in the range of 60\xb0 to 90\xb0 in a tangential direction of the circular plate.
6. The centrifugal compressor according to claims 2, wherein an angle made by a straight line connecting the shroud side of the fluid outlet with the hub side and an edge of the circular plate that is perpendicular to the rotary shaft is in the range of 60\xb0 to 90\xb0 in a tangential direction of the circular plate.
7. The centrifugal compressor according to claims 3, wherein an angle made by a straight line connecting the shroud side of the fluid outlet with the hub side and an edge of the circular plate that is perpendicular to the rotary shaft is in the range of 60\xb0 to 90\xb0 in a tangential direction of the circular plate.
8. The centrifugal compressor according to claims 1, wherein the shroud side is formed in an S-shape, and the hub side is formed in an S-shape.
9. The centrifugal compressor according to claims 2, wherein the shroud side is formed in an S-shape, and the hub side is formed in an S-shape.
10. The centrifugal compressor according to claims 3, wherein the shroud side is formed in an S-shape, and the hub side is formed in an S-shape.
11. The centrifugal compressor according to claim 1, wherein a width of the blade is gradually reduced from the end of the fluid discharging side of the flow channel to the downstream.
12. The centrifugal compressor according to claim 2, wherein a width of the blade is gradually reduced from the end of the fluid discharging side of the flow channel to the downstream.
13. The centrifugal compressor according to claim 1, wherein the end is formed in a cylindrical shape having elliptical surface such that a long axis is arranged in a direction of the flow channel and a short axis is arranged in a width direction of the blade.
14. The centrifugal compressor according to claim 2, wherein the end is formed in a cylindrical shape having elliptical surface such that a long axis is arranged in a direction of the flow channel and a short axis is arranged in a width direction of the blade.
15. The centrifugal compressor according to claim 1, wherein the end is formed in a semi-circular cylinder shape.
16. The centrifugal compressor according to claim 2, wherein the end is formed in a semi-circular cylinder shape.
17. The centrifugal compressor according to claim 1, wherein the end is formed in an edge shape.
18. The centrifugal compressor according to claim 2, wherein the end is formed in an edge shape.
19. An impeller of a centrifugal compressor comprising a rotary shaft and an impeller having a plurality of blades substantially radially disposed and protruding from a circular plate supported by the rotary shaft, and having flow channels formed between the blades, in order to suck fluid from a front area in a shaft direction by rotating the circular plate with the rotary shaft and then discharge the fluid, which increases in pressure while passing through the flow channels, in a centrifugal direction,
wherein, assuming that a blade angle of a shroud side facing the circular plate of the blade is a first angle and a blade angle of a hub side disposed at the circular plate is a second angle,
the shroud side is formed in a curved shape having an angle distribution from the front area in the shaft direction toward the centrifugal direction in which the first angle is the local maximum point before a substantially middle portion and the local minimum point after the substantially middle point, and
the hub side is formed in a curved shape having an angle distribution from the front area in the shaft direction toward the centrifugal direction in which the second angle is the maximum local point before the substantially middle portion.
20. A method of operating a centrifugal compressor including a rotary shaft and an impeller having a plurality of blades substantially radially disposed and protruding from a circular plate supported by the rotary shaft, and having flow channels formed between the blades, in order to suck fluid from a front area in a shaft direction by rotating the circular plate with the rotary shaft and then discharge the fluid, which increases in pressure while passing through the flow channels, in a centrifugal direction,
wherein, assuming that a blade angle of a shroud side facing the circular plate of the blade is a first angle and a blade angle of a hub side disposed at the circular plate is a second angle,
deceleration flow is promoted at a front half region of the flow channel and acceleration flow is promoted at a rear half region of the flow channel by the impeller that has the shroud side formed in a curved shape having an angle distribution from the front area in the shaft direction toward the centrifugal direction in which the first angle is the local maximum point before a substantially middle portion and the local minimum point after the substantially middle point, and the hub side is formed in a curved shape having an angle distribution from the front area in the shaft direction toward the centrifugal direction in which the second angle is the maximum local point before the substantially middle portion.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or excipient and at least one pyrazolo pyridine derivative according to Formula (I):
wherein G1is selected from H, optionally substituted alkyl, optionally substituted C3-C8-cycloalkyl alkyl, optionally substituted heterocycloalkyl alkyl, optionally substituted aryl alkyl and optionally substituted heteroaryl alkyl;
G2is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted alkyl aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, optionally substituted alkyl heteroaryl, optionally substituted heteroaryl alkyl, optionally substituted alkenyl aryl, optionally substituted aryl alkenyl, optionally substituted alkenyl heteroaryl, optionally substituted heteroaryl alkenyl, optionally substituted C3-C8-cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkyl C3-C8-cycloalkyl, optionally substituted C3-C8-cycloalkyl alkyl, optionally substituted alkyl heterocycloalkyl and optionally substituted heterocycloalkyl alkyl;
G3is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted alkyl aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, optionally substituted alkyl heteroaryl, optionally substituted heteroaryl alkyl, optionally substituted alkenyl aryl, optionally substituted aryl alkenyl, optionally substituted alkenyl heteroaryl, optionally substituted heteroaryl alkenyl, optionally substituted C3-C8-cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkyl C3-C8-cycloalkyl, optionally substituted C3-C8-cycloalkyl alkyl, optionally substituted alkyl heterocycloalkyl and optionally substituted heterocycloalkyl alkyl;
G4is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted alkyl aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, optionally substituted alkyl heteroaryl, optionally substituted heteroaryl alkyl, optionally substituted alkenyl aryl, optionally substituted aryl alkenyl, optionally substituted alkenyl heteroaryl, optionally substituted heteroaryl alkenyl, optionally substituted C3-C8-cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkyl C3-C8-cycloalkyl, optionally substituted C3-C8-cycloalkyl alkyl, optionally substituted alkyl heterocycloalkyl and optionally substituted heterocycloalkyl alkyl;
G5is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted alkyl aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, optionally substituted alkyl heteroaryl, optionally substituted heteroaryl alkyl, optionally substituted alkenyl aryl, optionally substituted aryl alkenyl, optionally substituted alkenyl heteroaryl, optionally substituted heteroaryl alkenyl, optionally substituted C3-C8-cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkyl C3-C8-cycloalkyl, optionally substituted C3-C8-cycloalkyl alkyl, optionally substituted alkyl heterocycloalkyl and optionally substituted heterocycloalkyl alkyl; or pharmaceutically acceptable salts thereof.
2. The pharmaceutical composition according to claim 1, wherein G1is H.
3. The pharmaceutical composition according to claim 1, wherein G1is optionally substituted aryl alkyl and optionally substituted heteroaryl alkyl.
4. The pharmaceutical composition according to claim 1, wherein G1is optionally substituted alkyl.
5. The pharmaceutical composition according to claim 1, wherein G2is selected from optionally substituted aryl and optionally substituted heteroaryl.
6. The pharmaceutical composition according to claim 1, wherein G3is H.
7. The pharmaceutical composition according to claim 1, wherein G3is optionally substituted alkyl.
8. The pharmaceutical composition according to claim 1, wherein G3is optionally substituted aryl.
9. The pharmaceutical composition according to claim 1, wherein G4is selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl.
10. The pharmaceutical composition according to claim 1, wherein G4is selected from optionally substituted aryl alkyl and optionally substituted heteroaryl alkyl.
11. The pharmaceutical composition according to claim 1, wherein G4is selected from optionally substituted heterocycloalkyl alkyl and optionally substituted C3-C8-cycloalkyl alkyl.
12. The pharmaceutical composition according to claim 1, wherein G4is optionally substituted heterocycloalkyl.
13. The pharmaceutical composition according to claim 1, wherein G5is H.
14. The pharmaceutical composition according to claim 1, wherein the pyrazolo pyridine derivative is selected from the following group:
4-methyl-2-phenyl-5-(thiophen-2-ylmethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H.5H)-dione;
2-(1,3-benzothiazol-2-yl)-5-2-(1H-imidazol-4-yl)ethyl-4-methyl-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-5-2-(1H-indol-3-yl)ethyl-4-methyl-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-methyl-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
5-(furan-2-ylmethyl)-4-methyl-2-phenyl-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-{2-(1,3-benzothiazol-2-yl)-4-methyl-3,6-dioxo-1,2,3,6-tetrahydro-5H-pyrazolo 4,3-cpyridin-5-ylmethyl}benzoic acid;
4-methyl-2-phenyl-5-(pyridin-3-ylmethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-methyl-2-phenyl-5-(2-phenylethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
5-2-(4-acetylpiperazin-1-ypethyl-2-(1,3-benzothiazol-2-yl)-4-methyl-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-methyl-5-(2-methylbutyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-5-2-(4-methoxyphenyl)ethyl-4-methyl-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-5-2-(4-hexanoylpiperazin-1-yl)ethyl-4-methyl-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-1-benzyl-5-(furan-2-ylmethyl) -4-methyl-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
5-2-(1H-indo1-3-yl)ethyl-4-methyl-1-(3-methylbenzyl)-2-phenyl-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
1-(4-fluorobenzyl)-5-2-(1H-indol-3-yl)ethyl-4-methyl-2-phenyl-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
1-(2-chlorobenzyl)-4-methyl-5-3-(2-oxopyrrolidin-1-yl)propyl-2-phenyl-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-1-benzyl-4-methyl-5-(tetrahydrofuran-2-ylmethyl)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
1-(4-chlorobenzyl)-5-2-(1H-imidazol-4-yl)ethyl-4-methyl-2-phenyl-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
5-(1,3-benzodioxol-5-ylmethyl)-4-methyl-2-phenyl-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
5-benzyl-4-methyl-2-phenyl-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
5-benzyl-2-(4-fluorophenyl)-4-methyl-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
5-benzyl-2-(4-methoxyphenyl)-4-methyl-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-methyl-5-morpholin-4-yl-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
5-benzyl-4-methyl-2-(4-nitrophenyl)-1H-pyrazolo 4,3-cpyridine-3,6(2H, 5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-methyl-1-(3-methylbenzyl)-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-1-(4-fluorobenzyl)-4-methyl-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-methyl-1-(4-methylbenzyl)-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-1-(2-chlorobenzyl)-4-methyl-5-morpholin-4-yl-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-1-(4-bromobenzyl)-4-methyl-5-(2-morpholin-4-ylethyl)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-2-(1,3-benzothiazol-2-yl)-4-methyl-5-(3-morpholin-4-ylpropyl)-3,6-dioxo-2,3,5,6-tetrahydro-1H-pyrazolo 4,3-cpyridin-1-yl-N-phenylacetamide;
4-methyl-2-phenyl-5-(tetrahydrofuran-2-ylmethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-methyl-5-(2-phenylethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
5-2-(1H-indo1-3-yl)ethyl-4-methyl-2-phenyl-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-methyl-5-morpholin-4-yl-2-phenyl-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-1-(2-chlorobenzyl)-4-methyl-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
5-benzyl-4-ethyl-2-(4-fluorophenyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(2-phenylethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-morpholin-4-yl-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-methyl-5-(2-morpholin-4-ylethyl)-2-phenyl-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-5-morpholin-4-yl-2-phenyl-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-methyl-2-(2-methylphenyl)-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-methyl-1-(pyridin-2-ylmethyl)-5-(tetrahydrofuran-2-ylmethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(pyridin-2-ylmethyl) -1H-pyrazolo4,3-cpyridine-3,6 (2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(2-methoxyethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(4-methylpiperazin-1-yl)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-1-(4-methylbenzyl)piperidin-4-yl-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(pyridin-2-ylmethyl)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo4,3-cpyridine-3,6 (2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(2-methoxyethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
5-(2-morpholin-4-ylethyl)-2-pyridin-2-yl-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2,4-diphenyl-5-(pyridin-3-ylmethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(2-chlorophenyl)-4-ethyl-5-(pyridin-3-ylmethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-methyl-2-(2-methylphenyl)-5-(pyridin-2-ylmethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-5-(3-morpholin-4-ylpropyl)-2-4-(trifluoromethyl)phenyl-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-5-(3-morpholin-4-ylpropyl)-2-4-(trifluoromethoxy)phenyl-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-(2,5-difluorophenyl)-4-ethyl-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo4,3-cpyridine-3,6 (2H,5H)-dione; or
4-ethyl-2-(2-methoxyphenyl)-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo4,3-cpyridine-3,6 (2H,5H)-dione.
15. A method of preparing a pharmaceutical composition comprising combining a pyrazolo pyridine derivative according to claim 1, or pharmaceutically acceptable salts thereof, with a pharmaceutically acceptable carrier, excipient or diluent.
16. A method for the treatment of a patient suffering from disease or condition selected from hypertension, atherosclerosis, pulmonary fibrosis, pulmonary hypertension, Alzheimer’s disease, diabetes, asthma, hearing loss and balance problems in response to ototoxic drugs, vascular injuries after balloon surgery, inflammation, cardiovascular complications of Type I or Type II diabetes, intimal hyperplasia, coronary heart disease, cerebral, coronary or arterial vasospasm, endothelial dysfunction, heart failure, peripheral artery disease, restenosis, trauma caused by a stent, stroke, ischemic attack, vascular complications after organ transplantation, viral or bacterial infections, myocardial infarction, platelet aggregation, angina pectoris, aneurysm, aortic dissection, ischemic heart disease, cardiac hypertrophy, pulmonary embolus, thrombotic events, injury caused after ischemia by restoration of blood flow or oxygen delivery in or an transplantation, open heart surgery angioplasty, hemorrhagic shock, angioplasty of ischemic organs, bronchial asthma, bronchitis, allergic rhinitis, adult respiratory syndrome, viral lung infection (influenza), pulmonary hypertension, chronic obstructive pulmonary diseases (COPD), hay fever, obesity, metabolic syndrome, Type II diabetes, soriasis eczema, dermatitis, wound healing, scar formation, osteoporosis, osteoporasis, osteosclerosis, periodontitis, hyperparathyroidism, Huntington’s disease, amyotrophic lateral sclerosis, epilepsy, muscular dystrophy, leukoencephalopathies, leukodystrophies, diabetic nephropathy, renal failure, glomerulonephritis, nephrotoxicity of aminoglycosides and platinum compounds, hyperactive bladder, erectile dysfunction, fertility disorders, prostatic hypertrophy, benign prostatic hypertrophy cataracts re-opacification of the lens post cataract surgery, diabetic retinopathy, presbyacusis, tinnitus, Meniere’s disease and other balance problems, utriculolithiasis, vestibular migraine, noise induced hearing loss, inflammatory bowel disease, sepsis, septic shock, adult respiratory distress syndrome, pancreatitis, shock induced by trauma, bronchial asthma, allergic rhinitis, rheumatoid arthritis, chronic rheumatoid arthritis, arteriosclerosis, intracerebral hemorrhage, cerebral infarction, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, myelitis, ankylosing spondylitis, Reuter syndrome psoriatic arthritis, spondylarthritis, juvenile arthritis, juvenile ankylosing spondylitis, reactive arthritis, gonococcal arthritis, tuberculous arthritis, viral arthritis, bacterial arthritis, syphilitic arthritis, Lyme disease, polyarteritis nodosa, anaphylactic angiitis, Luegenec granulomatosis, rheumatoid polymyalgia, articular cell rheumatism, calcium crystal deposition arthritis, pseudogout, non-arthritic rheumatism, bursitis, tendosynovitis, epicondyle inflammation (tennis elbow), carpal tunnel syndrome, mixed form of arthritis, neuropathic arthropathy, hemorrhagic arthritis, vascular peliosis, hypertrophic osteoarthropathy, multicentric reticulohistiocytosis, arthritis induced by specific diseases, blood pigmentation, sickle cell disease and other hemoglobin abnormality, hyperlipoproteinemia, dysgammaglobulinemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Bechet’s disease, systemic autoimmune disease erythematosus, multiple sclerosis, Crohn’s disease, chronic inflammatory bowel diseases (IBD), liver fibrosis, alcohol induced fibrosis, steatosis, non alcoholic steatohepatitis, pain, prostate cancer, breast cancer, pancreatic cancer or renal cancer comprising administering a composition according to claim 1, to a patient in need of treatment of said disease or condition.
17. The composition according to claim 1, wherein said pyrazolo pyridine derivative has Formula (I):
wherein G1, G2, G3, G4and G5are as defined in claim 1, and said derivative is selected from the group consisting of:
5-benzyl-4-ethyl-2-(4-fluorophenyl)-1H-pyrazolo4,3cpyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(2-phenylethyl)-1Hpyrazolo 4,3-cpyridine-3,6(2,H5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-morpholin-4-yl-1Hpyrazolo4,3-cpyridine-3,6(2,H5H)-dione;
2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1Hpyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-methyl-2-(2-methylphenyl)-5-(3-morpholin-4-ylpropyl)1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-{1,3-benzothiazol-2-yl)-4-methyl-1-(pyridin-2-ylmethyl)5-(tetrahydrofuran-2-ylmethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H}-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(pyridin-2-ylmethyl)1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(3-morpholin-4ylpropyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(2-methoxyethyl)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(4-methylpiperazin-1y1)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(pyridin-2-ylmethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(2-methoxyethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
5-(2-morpholin-4-ylethyl)-2-pyridin-2-yl-1H-pyrazolo4,3cpyridine-3,6(2H,5H)-dione;
4-ethyl-5-(3-morpholin-4-ylpropyl)-2-4-(trifluoromethyl)phenyl)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-5-(3-morpholin-4-ylpropyl)-2-4-(trifluoromethoxy)phenyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione; or
2-(2,5-difluorophenyl)-4-ethyl-5-(3-morpholin-4-ylpropyl)1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione; and pharmaceutically acceptable salts thereof.
18. The method according to claim 16, wherein said disease or condition is selected from hypertension, atherosclerosis, pulmonary fibrosis, pulmonary hypertension, Alzheimer’s disease, diabetes, asthma, hearing loss and balance problems in response to ototoxic drugs, or vascular injuries after balloon surgery.
19. The method according to claim 16, wherein said disease or condition is inflammation.
20. A pyrazolo pyridine derivative selected from the group consisting of:
5-benzyl-4-ethyl-2-(4-fluorophenyl)-1H-pyrazolo4,3cpyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(2-phenylethyl)-1Hpyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-morpholin-4-yl-1Hpyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1Hpyrazolo 4,3-cpyridine-3,6(2,5H)-dione;
4-methyl-2-(2-methylphenyl)-5-(3-morpholin-4-ylpropyl)1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-{1,3-benzothiazol-2-yl)-4-methyl-1-(pyridin-2-ylmethyl)5-(tetrahydrofuran-2-ylmethyl)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H}-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(pyridin-2-ylmethyl)1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(3-morpholin-4ylpropyl)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(2-methoxyethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(4-methylpiperazin-1yl)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(pyridin-2-ylmethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(2-methoxyethyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,5H)-dione;
5-(2-morpholin-4-ylethyl)-2-pyridin-2-yl-1H-pyrazolo4,3cpyridine-3,6(2H,5H)-dione;
4-ethyl-5-(3-morpholin-4-ylpropyl)-2-4-(trifluoromethyl)phenyl)-1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione;
4-ethyl-5-(3-morpholin-4-ylpropyl)-2-4-(trifluoromethoxy)phenyl)-1H-pyrazolo4,3-cpyridine-3,6(2H,-5H)-dione;
2-(2,5-difluorophenyl)-4-ethyl-5-(3-morpholin-4-ylpropyl)1H-pyrazolo 4,3-cpyridine-3,6(2H,5H)-dione; and pharmaceutically acceptable salts thereof.
21. The method according to claim 16, wherein said disease or condition is cardiovascular complications of Type I or Type II diabetes, intimal hyperplasia, coronary heart disease, cerebral, coronary or arterial vasospasm, endothelial dysfunction, heart failure, peripheral artery disease, restenosis, trauma caused by a stent, stroke, ischemic attack, vascular complications after organ transplantation, viral or bacterial infections, myocardial infarction, platelet aggregation, angina pectoris, aneurysm, aortic dissection, ischemic heart disease, cardiac hypertrophy, pulmonary embolus, thrombotic events, injury caused after ischemia by restoration of blood flow or oxygen delivery in organ transplantation, open heart surgery, angioplasty, hemorrhagic shock, or angioplasty of ischemic organs.
22. The method according to claim 16, wherein said disease or condition is bronchial asthma, bronchitis, allergic rhinitis, adult respiratory syndrome, viral lung infection (influenza), pulmonary hypertension or chronic obstructive pulmonary diseases (COPD).
23. The method according to claim 16, wherein said disease or condition is hay fever.
24. The method according to claim 16, wherein said disease or condition is obesity, metabolic syndrome or Type II diabetes.
25. The method according to claim 16, wherein said disease or condition is psoriasis, eczema, dermatitis, wound healing or scar formation.
26. The method according to claim 16, wherein said disease or condition is osteoporosis, osteoporasis, osteosclerosis, periodontitis, or hyperparathyroidism.
27. The method according to claim 16, wherein said disease or condition is Huntington’s disease, amyotrophic lateral sclerosis, epilepsy, muscular dystrophy, leukoencephalopathies or leukodystrophies.
28. The method according to claim 16, wherein said disease or condition is diabetic nephropathy, renal failure, glomerulonephritis, nephrotoxicity of aminoglycosides and platinum compounds or hyperactive bladder.
29. The method according to claim 16, wherein said disease or condition is erectile dysfunction, fertility disorders, prostatic hypertrophy or benign prostatic hypertrophy.
30. The method according to claim 16, wherein said disease or condition is cataracts, re-opacification of the lens post cataract surgery, or diabetic retinopathy.
31. The method according to claim 16, wherein said disease or condition presbyacusis, tinnitus, Meniere’s disease and other balance problems, utriculolithiasis, vestibular migraine, or noise induced hearing loss.
32. The method according to claim 16, wherein said disease or condition is inflammatory bowel disease, sepsis, septic shock, adult respiratory distress syndrome, pancreatitis, shock induced by trauma, bronchial asthma, allergic rhinitis, rheumatoid arthritis, chronic rheumatoid arthritis, arteriosclerosis, intracerebral hemorrhage, cerebral infarction, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, myelitis, ankylosing spondylitis, Reuter syndrome, psoriatic arthritis, spondylarthritis, juvenile arthritis, juvenile ankylosing spondylitis, reactive arthritis, gonococcal arthritis, tuberculous arthritis, viral arthritis, bacterial arthritis, syphilitic arthritis, Lyme disease, polyarteritis nodosa, anaphylactic angiitis, Luegenec granulomatosis, rheumatoid polymyalgia, articular cell rheumatism, calcium crystal deposition arthritis, pseudogout, non-arthritic rheumatism, bursitis, tendosynovitis, epicondyle inflammation (tennis elbow), carpal tunnel syndrome, mixed form of arthritis, neuropathic arthropathy, hemorrhagic arthritis, vascular peliosis, hypertrophic osteoarthropathy, multicentric reticulohistiocytosis, arthritis induced by specific diseases, blood pigmentation, sickle cell disease and other hemoglobin abnormality, hyperlipoproteinemia, dysgammaglobulinemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Bechet’s disease, systemic autoimmune disease erythematosus, multiple sclerosis, Crohn’s disease, or chronic inflammatory bowel diseases (IBD).
33. The method according to claim 16, wherein said disease or condition is liver fibrosis, alcohol induced fibrosis, steatosis or non alcoholic steatohepatitis.
34. The method according to claim 16, wherein said disease or condition is pain.
35. The method according to claim 16, wherein said disease or condition is pancreatic cancer, breast cancer, prostatic carcinoma or renal cell carcinoma.

1. An apparatus for charging a battery, comprising:
a charging component configured to receive an amount of voltage on a power bus connectable to an external device, wherein the charging component charges the battery with the amount of voltage received;
an authentication component configured to authenticate the apparatus with the external device via a plurality of signal lines, wherein the authentication component is configured to transmit one or more authentication signals on one or more of the plurality of signal lines; and
a configuration component configured to transmit a modified voltage signal and a modified current signal to the external device via the plurality of signal lines, wherein the modified voltage signal and the modified current signal are operable to cause the external device to modify the amount of voltage transmitted to the power bus.
2. The apparatus of claim 1, wherein the charging component is directly connected to the power bus.
3. The apparatus of claim 1, wherein the charging component is further configured to include a halver directly connected to the power bus, wherein the halver is configured to divide the amount of voltage in half.
4. The apparatus of claim 1, wherein the modified voltage signal corresponds to an amount of voltage the apparatus requests, and wherein the modified current signal corresponds to a threshold amount of current that the external device is limited to transmitting to the apparatus.
5. The apparatus of claim 1, further comprising a detection component configured to determine the amount of voltage received from the external device.
6. The apparatus of claim 5, further comprising:
a control component configured to modify the modified voltage signal and the modified current signal transmitted by the configuration component based at least in part on the amount of voltage received and whether the apparatus is authenticated;
wherein the control component is configured to be prevented from operating when the apparatus fails to authenticate; and
wherein the power bus receives a default amount of voltage transmitted by the external device when the authentication component fails to authenticate the apparatus with the external device.
7. The apparatus of claim 5, wherein the detection component determines, either continuously or periodically, the amount of voltage received by the charging component.
8. The apparatus of claim 1, wherein the apparatus operates in conformance to the Universal Serial Bus (USB) Specification, wherein the power bus comprises a voltage bus (VBUS) and the plurality of signal lines comprise a D\u2212 signal line and a D+ signal line.
9. The apparatus of claim 8, wherein the apparatus further operates in a USB On-The-Go (OTG) configuration, and wherein the apparatus simultaneously receives an amount of voltage on the power bus and transmits one or more signals on the plurality of signal lines.
10. The apparatus of claim 1, wherein the external device is a High Voltage Dedicated Charging Port (HVDCP) device, wherein the power bus comprises a voltage bus (VBUS) and the plurality of signal lines comprise a D\u2212 signal line and a D+ signal line.
11. The apparatus of claim 10, wherein the charging component determines whether the external device is an HVDCP device based on the amount of voltage received by charging component on the VBUS.
12. The apparatus of claim 1, wherein the battery is configured as at least one or both of a single cell battery or a multiple cell battery.
13. The apparatus of claim 1, wherein the authentication component is configured to authenticate the apparatus with the external device either initially upon connecting with the external device or periodically.
14. An apparatus for charging a battery, comprising:
means for receiving an amount of voltage on a power bus connectable to an external device, wherein the means for receiving charges the battery with the amount of voltage received;
means for authenticating the apparatus with the external device via a plurality of signal lines, wherein the means for authenticating is configured to transmit one or more authentication signals on one or more of the plurality of signal lines; and
means for transmitting a modified voltage signal and a modified current signal to the external device via the plurality of signal lines, wherein the modified voltage signal and the modified current signal are operable to cause the external device to modify the amount of voltage transmitted to the power bus.
15. A method for charging a battery of a portable device, comprising:
receiving, by a charging component, an amount of voltage on a power bus connectable to an external device, wherein the charging component charges the battery with the amount of voltage received;
authenticating, by an authentication component, the portable device with the external device via a plurality of signal lines, wherein the authentication component is configured to transmit one or more authentication signals on one or more of the plurality of signal lines; and
transmitting, by a configuration component, a modified voltage signal and a modified current signal to the external device via the plurality of signal lines, wherein the modified voltage signal and the modified current signal are operable to cause the external device to modify the amount of voltage transmitted to the power bus.
16. The method of claim 15, wherein the charging component is directly connected to the power bus.
17. The method of claim 15, wherein the charging component is configured to include a halver directly connected to the power bus, wherein the halver is configured to divide the amount of voltage in half.
18. The method of claim 15, wherein the modified voltage signal corresponds to an amount of voltage the portable device requests, and wherein the modified current signal corresponds to a threshold amount of current that the external device is limited to transmitting to the portable device.
19. The method of claim 15, further comprising determining, by a detection component, the amount of voltage received from the external device.
20. The method of claim 19, further comprising:
modifying, by a control component, the modified voltage signal and the modified current signal transmitted by the configuration component based at least in part on the amount of voltage received and whether the portable device is authenticated;
preventing the control component from operating when the portable device fails to authenticate; and
receiving, by the power bus, a default amount of voltage transmitted by the external device when the authentication component fails to authenticate the portable device with the external device.
21. The method of claim 19, determining, by the detection component, either continuously or periodically, the amount of voltage received by the charging component.
22. The method of claim 15, wherein the portable device operates in conformance to the Universal Serial Bus (USB) Specification, wherein the power bus comprises a voltage bus (VBUS) and the plurality of signal lines comprise a D\u2212 signal line and a D+ signal line.
23. The method of claim 22, wherein the portable device further operates in a USB On-The-Go (OTG) configuration, and wherein the portable device simultaneously receives an amount of voltage on the power bus and transmits one or more signals on the plurality of signal lines.
24. The method of claim 15, wherein the external device is a High Voltage Dedicated Charging Port (HVDCP) device, wherein the power bus comprises a voltage bus (VBUS) and the plurality of signal lines comprise a D\u2212 signal line and a D+ signal line.
25. The method of claim 24, further comprising determining, by the charging component, whether the external device is an HVDCP device based on the amount of voltage received by charging component on the VBUS.
26. The method of claim 15, wherein the battery is configured as at least one or both of a single cell battery or a multiple cell battery.
27. The method of claim 15, further comprising authenticating, by the authenticating component, the portable device with the external device either initially upon connecting with the external device or periodically.
28. A computer-readable medium storing computer executable code for charging a battery of a portable device, comprising:
code for receiving, by a charging component, an amount of voltage on a power bus connectable to an external device, wherein the charging component charges the battery with the amount of voltage received;
code for authenticating, by an authentication component, the portable device with the external device via a plurality of signal lines, wherein the authentication component is configured to transmit one or more authentication signals on one or more of the plurality of signal lines; and
code for transmitting, by a configuration component, a modified voltage signal and a modified current signal to the external device via the plurality of signal lines, wherein the modified voltage signal and the modified current signal are operable to cause the external device to modify the amount of voltage transmitted to the power bus.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1.-18. (canceled)
19. A method for coating double sides with a coating solution which supplies a coating solution to both main surfaces of a substrate to be processed, and rotationally operates the substrate to be processed to spread the coating solution on both the main surfaces, thereby forming coating films on both the main surfaces of the substrate to be processed,
wherein the method holds the substrate to be processed so that the thickness direction of the substrate to be processed is a horizontal direction, rotates the substrate to be processed in a circumferential direction, and simultaneously jets the coating solution toward the substrate to be processed from a first coating solution nozzle which jets the coating solution onto one main surface of the substrate to be processed, and a second coating solution nozzle which is symmetrically arranged with respect to the first coating solution nozzle and a thickness center plane of the substrate to be processed, and jets the coating solution onto the other main surface of the substrate to be processed.
20. The method for coating double sides with a coating solution according to claim 19,
wherein the coating solution is jetted onto the inner peripheral portion and outer peripheral portion of the substrate to be processed from the first coating solution nozzle and the second coating solution nozzle.
21. The method for coating double sides with a coating solution according to claim 19,
wherein the amount of the coating solution jetted onto the inner peripheral portion from the first coating solution nozzle and the second coating solution nozzle is made larger than the amount of the coating solution jetted onto the outer peripheral portion of the substrate to be processed from the first and second coating solution nozzles.
22. The method for coating double sides with a coating solution according to claim 19, further comprising an edge rinsing step of arranging a container, which stores a rinsing solution and has the liquid level of the rinsing solution exposed through the top surface thereof, at a position where the outer edge of the substrate to be processed which is being rotated after the coating step is immersed in the rinsing solution.
23. The method for coating double sides with a coating solution according to claim 22,
wherein the edge rinsing step is performed while droplets consisting of the rinsing solution are sucked by a suction part which is arranged adjacent to the container.
24. The method for coating double sides with a coating solution according to claim 19, further comprising a coating solution nozzle cleaning step of jetting a rinsing solution from the head rinsing nozzle to clean the coating solution nozzle.
25. (canceled)
26. An edge rinsing method which removes a coating solution adhering to outer edges of both main surfaces of a substrate to be processed on which the coating solution has been coated, the edge rinsing method comprising:
an edge rinsing step of holding the substrate to be processed so that the thickness direction of the substrate to be processed is a horizontal direction, thereby rotating the substrate to be processed in a circumferential direction, and arranging a container which stores a rinsing solution, and has the liquid level of the rinsing solution exposed through the top surface of the container, at a position where the outer edges of the substrate to be processed which is rotating are immersed in the rinsing solution.
27. The edge rinsing method according to claim 26, further comprising an attachingdetaching step which attaches and detaches the substrate to be processed tofrom a holding mechanism which holds the substrate to be processed, and the attachingdetaching step is performed by moving the container in a horizontal direction and in a vertical direction by a container moving mechanism which supports the container, thereby retreating the container.
28. The edge rinsing method according to claim 26,
wherein the edge rinsing step is performed while droplets consisting of the rinsing solution are sucked by a suction part which is arranged adjacent to the container.